Discoidin Domain Receptor

Discoidin domain receptors (DDRs) are receptor tyrosine kinases with the unique ability among receptor tyrosine kinases to respond to collagen. Several signaling molecules have been implicated in DDR signaling, including Shp-2, Src, and MAPK pathways. DDRs have been reported to induce the expression of various genes including matrix metalloproteinases and bone morphogenetic proteins, but the regulatory mechanisms underlying DDR-induced gene expression remain to be determined. DDRs regulate cell-collagen interactions in normal and pathological conditions and thus are emerging as major sensors of collagen matrices and potential novel therapeutic targets.
## Discoidin Domain Receptor Inhibitors

### DDR Inhibitor
- **Cat. No.:** HY-W018931
- DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC₅₀ of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.
- **Purity:** 97.85%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg

### DDR-TRK-1
- **Cat. No.:** HY-100695
- DDR-TRK-1 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC₅₀ value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### DDR1-IN-1
- **Cat. No.:** HY-13979
- DDR1-IN-1 is a potent and selective DDR1 receptor inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM).
- **Purity:** 98.20%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### DDR1-IN-1 dihydrochloride
- **Cat. No.:** HY-13979A
- DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM).
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### DDR1-IN-2
- **Cat. No.:** HY-U00444
- DDR1-IN-2 is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC₅₀ of 13.1 nM, and also less potently inhibits DDR2, with an IC₅₀ of 203 nM.
- **Purity:** 98.62%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

### DDR1-IN-5
- **Cat. No.:** HY-133669
- DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC₅₀ of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC₅₀ of 4.1 nM. DDR1-IN-5 has anti-cancer activity.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### DDR1-IN-6
- **Cat. No.:** HY-133670
- DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC₅₀ of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC₅₀ of 9.7 nM. DDR1-IN-6 has anti-cancer activity.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### Merestinib (LY2801653)
- **Cat. No.:** HY-15514
- Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Kᵢ = 2 nM) with anti-tumor activities.
- **Purity:** 99.99%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Merestinib dihydrochloride (LY2801653 dihydrochloride)
- **Cat. No.:** HY-15514A
- Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Kᵢ = 2 nM) with anti-tumor activities.
- **Purity:** 99.02%
- **Clinical Data:** Phase 2
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

---

Tel: 609-228-6898   Fax: 609-228-5909   Email: sales@MedChemExpress.com
| **Sitravatinib**  
(MGCD516; MG-516) | **Cat. No.** HY-16961 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with $IC_{50}$ of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.85%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: Phase 2</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg</td>
<td></td>
</tr>
</tbody>
</table>

| **Sitravatinib malate**  
(MGCD516 malate; MG-516 malate) | **Cat. No.** HY-16961A |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with $IC_{50}$ of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.</td>
<td></td>
</tr>
<tr>
<td>Purity: &gt;98%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>VU6015929</strong></th>
<th><strong>Cat. No.</strong> HY-135401</th>
</tr>
</thead>
<tbody>
<tr>
<td>VU6015929 is a potent, selective and orally active dual discoidin domain receptor 1/2 (DDR1/2) inhibitor with $IC_{50}$ of 4.67 nM and 7.39 nM, respectively. VU6015929 potently blocks collagen-induced DDR1 activation and collagen-IV production.</td>
<td></td>
</tr>
<tr>
<td>Purity: 98.10%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>WRG-28</strong></th>
<th><strong>Cat. No.</strong> HY-114169</th>
</tr>
</thead>
<tbody>
<tr>
<td>WRG-28 is a selective, extracellularly acting DDR2 allosteric inhibitor with an $IC_{50}$ of 230 nM. WRG-28 uniquely inhibits receptor-ligand interactions via allosteric modulation of the receptor.</td>
<td></td>
</tr>
<tr>
<td>Purity: 99.42%</td>
<td></td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td></td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>